Zonagen (zona) - good buy? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: khrnyc who wrote (1987)	1/23/1998 9:05:00 PM
From: Dr. Voodoo	of 7041

Dr. Rubin, "Does anybody have the Imhof study referred to by Asencio (Jan 15, 1998)? It would be good to know what the starting dosages were...." As I have stated on this thread before, I would not doubt Asensio's numbers just like I wouldn't doubt yours, or Zonagen's. As an investor and scientist it is up to me to be able to interpret them. Without doubting or looking at the numbers from the paper, I will make a couple of simplifying assumptions. These are purely speculative and I would appreciate any help by getting the actual data from the study. Even some expert doc's could chime in too! Assumption #1. Imhof did not give his patients a toxic dose of phentolamine. Assumption #2 The dosages were given orally. I think these are reasonable assumptions. Assumption #3 The toxicity and therapeutic index of phentolamine hasn't changed,for the average person, significantly since 1975. This one might be a little shakey. Given this information, could I not presume that I could give someone a Phentolamine pill at a non-toxic dose and achieve the same or higher blood levels of Phentolamine? Does this point not make the Zonagen patent and the question of starting doses moot? Rob

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next